# Beijing Golden Key Gene Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/beijing-golden-key-gene-technology-co

- Industry: Biotechnology
- Headquarters: Beijing, China
- Website: www.genskey.com
- Total disclosed funding: $56M
- Latest round: Series C (Jun 1, 2021)
- Investors on record: 11

## About

Established in 2017 and based in Beijing, China, Beijing Golden Key Gene Technology Co., Ltd. is a medical company that focuses on clinical diagnosis based on gene technology. In 2017, the company changed its name from Beijing Golden Key Medical Technology to Beijing Golden Key Biological Technology. In 2018, it changed its name from Beijing Golden Key Biological Technology to Beijing Golden Key Gene Technology Co., Ltd. In 2019, it launched a respiratory infection diagnostic product. The company has a subsidiary called Golden Key Zhizao. Ms. Zhi Jiang, the founder and CEO of the company, served as the director of BGI Gene Technology Service Division and the president of Nuohe Zhiyuan.

The company engages in the research and development of pathogenic diagnostic products. Its main products include the COVID-19 detection product series and the pathogen metagenomic product series. The company also provides testing services for the COVID-19 and metagenomics. The company's products are used in hospitals and medical laboratories.

## Funding rounds

- Series C, Jun 1, 2021 — Oriza Holdings, Taikang Investment
- Series C, Apr 21, 2021 — CPE Funds Management
- Series C, Nov 2, 2020, $34M — Legend Capital, Huagai Capital, YuanBio Venture, Apricot Capital
- Series B, Jan 24, 2020, $7.2M — Legend Capital, Fortune Capital
- Series B, Nov 18, 2019, $14M — SB China Venture Capital, Linchuang Capital, Yuanju Capital Asset Management
- Series A, Apr 1, 2019 — Legend Capital

## Investors

- Legend Capital — Series A, Series B, Series C
- SB China Venture Capital (https://capitalatlas.ai/funds/sb-china-venture-capital) — Series B
- Linchuang Capital (https://capitalatlas.ai/funds/linchuang-capital) — Series B
- Yuanju Capital Asset Management (https://capitalatlas.ai/funds/yuanju-capital-asset-management) — Series B
- Fortune Capital — Series B
- Huagai Capital (https://capitalatlas.ai/funds/huagai-capital) — Series C
- YuanBio Venture (https://capitalatlas.ai/funds/yuanbio-venture) — Series C
- Apricot Capital (https://capitalatlas.ai/funds/apricot-capital) — Series C
- CPE Funds Management (https://capitalatlas.ai/funds/cpe-funds-management) — Series C
- Oriza Holdings (https://capitalatlas.ai/funds/oriza-holdings) — Series C
- Taikang Investment (https://capitalatlas.ai/funds/taikang-investment) — Series C